JP Patent

JP5957003B2 — 変異体選択的ｅｇｆｒ阻害剤およびその使用

Assigned to セルジーン アヴィロミクス リサーチ， インコーポレイテッド · Expires 2016-07-27 · 10y expired

What this patent protects

Patent listed against Imbruvica.

Drugs covered by this patent

Patent Metadata

Patent number
JP5957003B2
Jurisdiction
JP
Classification
—
Expires
2016-07-27
Drug substance claim
No
Drug product claim
No
Assignee
セルジーン アヴィロミクス リサーチ， インコーポレイテッド
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.